阻塞性睡眠呼吸暂停患者的勃起功能障碍:持续的气道正压的影响
Hyeyun Kim1, Keun Tae Kim2, Won Chul Shin3
1Department of Neurology, Sleep Medicine Research Center, College of Medicine, Catholic Kwandong University, International St. Mary's Hospital, Incheon, Korea.
概括
阻塞性睡眠呼吸暂停 (OSA) 与勃起功能障碍 (ED) 有关. 持续的正气道压力 (CPAP) 治疗在韩国患者中显著改善了ED,生活质量是关键因素.
科学领域:
- 睡眠医学 睡眠医学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 男人的健康 男人的健康
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 是一种常见的睡眠障碍.
- 勃起功能障碍 (ED) 是与OSA相关的普遍并发症.
- 了解OSA和ED之间的联系对于患者护理至关重要.
研究的目的:
- 调查韩国男性患有OSA的患者中ED的患病率和影响.
- 评估持续正气道压力 (CPAP) 疗法在治疗OSA患者的ED治疗中的有效性.
- 为了确定影响CPAP治疗后ED改善的因素.
主要方法:
- 来自四个睡眠中心的87名男性OSA患者的队列被纳入.
- 患者完成了身体测量和验证的问卷,包括国际勃起功能指数 (IIEF) 和SF36生活质量评估.
- 数据是在CPAP治疗开始前和三个月后收集的.
主要成果:
- 通过CPAP治疗,ED症状显著改善,IIEF评分增加表明了这一点.
- 在CPAP使用的持续时间和ED改善的程度之间没有发现显著的相关性.
- 生活质量评估得分SF36被确定为ED改善的重要预测指标.
结论:
- 在韩国OSA患者中,ED很常见,可以通过CPAP治疗来缓解.
- CPAP疗法对改善ED有希望,可能受到心理因素和整体生活质量的影响.
- 需要进一步的研究来阐明CPAP对OSA患者ED影响的机制.
关键词:
勃起功能障碍是因为勃起功能障碍.呼吸暂停低呼吸指数 (AHI) 是一个指数.持续的正气道压力 (CPAP) 是指持续的正气道压力.阻塞性睡眠呼吸暂停 (OSA) 是一种睡眠 睡眠 睡眠 睡眠 睡眠更多相关视频
相关概念视频
Sleep Apnea
156
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
156
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
158
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
158
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
214
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
214
Mechanical Ventilation III: Noninvasive Ventilation
115
Noninvasive positive-pressure ventilation (NIPPV), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP) are essential methods in respiratory care. These ventilation techniques offer unique benefits for patients with various respiratory conditions, providing adequate support without requiring intubation. Let's explore how each method is crucial in improving patient outcomes and enhancing respiratory therapy.
Noninvasive Positive-Pressure Ventilation...
Noninvasive Positive-Pressure Ventilation...
115
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181


